Schering's Antipsychotic Saphris Should Have Easy Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Label for asenapine could be highly favorable on weight and adverse event issues given FDA's enthusiasm.
You may also be interested in...
Panel Recommends Schering's Saphris; Safety Profile Could Provide Niche
The atypical antipsychotic market should soon be seeing competition from a new entry with a novel formulation and a more attractive safety profile, after an FDA advisory committee voted strongly in favor of Schering Plough's Saphris (asenapine) for acute schizophrenia and bipolar disorder
Panel Recommends Schering's Saphris; Safety Profile Could Provide Niche
The atypical antipsychotic market should soon be seeing competition from a new entry with a novel formulation and a more attractive safety profile, after an FDA advisory committee voted strongly in favor of Schering Plough's Saphris (asenapine) for acute schizophrenia and bipolar disorder
Schering Plough's Saphris Gets Strong Nod From FDA Panel
A safety profile showing less impact on weight and metabolic parameters than other atypical antipsychotics could set asenapine apart in crowded class if it is approved.